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Abstract
Objective—To evaluate whether an electronic health record reminder improves rates of 
screening for type 2 diabetes (T2DM) in women with prior gestational diabetes (GDM).
Methods—We randomly allocated primary care providers (by clinic site) to a reminder for 
T2DM screening within the electronic health record or to usual care. Women with previous GDM 
were identified through an automated search of laboratory results and the problem list. We 
compared rates of screening during the study period (2010–2012) in women at intervention sites 
with those at control sites. With a sample size of 850 participants, we had 80% power to detect a 
15% difference in screening rates.
Results—We included 847 individuals seen at a participating clinic during the study period, of 
whom 471 were at a reminder clinic and 376 were at a control clinic. A similar proportion of 
women were screened for T2DM in both groups (N=265, 56.3% of the reminder group vs. N=206, 
54.8% of the control group, p=0.67; adjusted OR 1.04, 95% CI 0.79, 1.38. Patient characteristics 
associated with risk for diabetes including BMI (aOR per kg/m2 1.05, 95% CI 1.01, 1.08) and race 
(aOR for non-white race 2.14, 95% CI 1.57, 2.92) were significantly associated with screening.
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Conclusions—A simple electronic health record reminder did not increase the rate of diabetes 
screening in women with prior GDM.
Introduction
Gestational diabetes (GDM) affects 3–8% of pregnancies in the United States.(1) A 
diagnosis of GDM is associated with an increased risk for future type 2 diabetes; as many as 
50% of women with GDM will develop diabetes within 5 years of delivery.(2) 
Consequently, the American College of Obstetricians and Gynecologists and the American 
Diabetes Association recommend that women diagnosed with GDM undergo screening at 6–
12 weeks postpartum to detect type 2 diabetes, and continued screening for type 2 diabetes 
at least every three years.(3, 4) Despite these recommendations, screening rates remain 
suboptimal even in the immediate postpartum period.(5–8)
Previous interventions to increase diabetes screening have targeted obstetric providers in the 
postpartum period,(9, 10) however we are unaware of efforts targeting primary care 
providers. Provider-level barriers to ongoing diabetes screening among women with a 
history of GDM include lack of knowledge as well as poor communication between 
obstetricians and primary care providers about pregnancy complications.(11) Clinical 
decision support utilizing the electronic health record has shown promise as a system 
improvement that may improve quality of care.(12)
In a cluster randomized trial of electronic health record reminders conducted in our system, 
reminders improved rates of screening for hyperlipidemia in adults with chronic disease. 
(13) We therefore sought to study whether an electronic health record reminder in a primary 
care setting would increase screening for diabetes among women with a history of GDM.
Materials and Methods
We performed a cluster randomized trial of a reminder within the electronic health record to 
evaluate the impact on diabetes screening in women with a history of GDM. As our 
intervention targeted providers, we chose a cluster randomized design to avoid 
contamination by colleagues within participating practices. We included primary care sites 
from within the Partners HealthCare System, a non-profit network of outpatient and 
inpatient facilities founded by Brigham and Women’s Hospital and Massachusetts General 
Hospital based in Boston, Massachusetts. All of the participating sites utilize an internally-
developed electronic health record called the Longitudinal Medical Record (LMR). These 
23 clinics included community health centers, hospital-based practices and off-site practices 
and have consented to participate in LMR-based research projects. The Partners Institutional 
Review Board approved this study. The trial is registered at ClinicalTrials.gov (study 
identifier NCT01288144).
We randomized the sites stratified by primary hospital affiliation (Brigham and Women’s 
Hospital or Massachusetts General Hospital) and practice type (women’s health center, 
community health center or off-site practice) to balance provider and patient characteristics 
between the intervention and control groups. One site in which providers are housed in 
separate suites was divided into 4 clusters for randomization, resulting in 26 clusters in total. 
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Within each stratum, we used SAS to generate a random sequence, assigning 13 clusters to 
the intervention and 13 to be controls.
The LMR allows providers to maintain problem, medication and allergy lists, to view 
laboratory and radiology results, and to generate medication prescriptions and laboratory 
orders. The first screen visible when a clinician accesses the electronic record for a patient is 
called the summary screen, and is viewed each time the patient record is opened. The system 
includes several clinical reminders including cancer screening, chronic disease management 
and smoking cessation which are displayed on the summary screen when indicated. The 
diabetes screening reminder text read “Patient has a history of gestational diabetes and 
should be screened for type 2 diabetes.” For clinicians at intervention sites, the reminder was 
displayed within the summary screen along with any other clinical reminders each time the 
record was accessed. The diabetes screening reminder was not visible to providers practicing 
at control sites. At intervention sites, a drop-down menu with coded responses was displayed 
with the reminder (figure 1). Clicking on the reminder displayed provider education about 
the rationale and recommended screening strategies in women with a history of GDM as 
well as links to further information online. The reminder content was approved by an 
interdisciplinary committee of providers who use the LMR.
Patients and physicians were enrolled on the first occasion during the study period 
(November 25, 2010 to December 1, 2012) that a 1) provider at a participating site opened a 
patient chart within the LMR and 2) a reminder was generated. Women were therefore 
enrolled in the study at the time their provider accessed their chart. Each time that a clinician 
opened a patient chart within the LMR, an algorithm was run to identify women with a 
history of GDM and exclude women who were recently screened, were less than 3 months 
postpartum or had already been diagnosed with diabetes. The algorithm was developed with 
the input of the Partners electronic medical record clinical content committee, and 
prioritized specificity of GDM diagnosis over sensitivity. The algorithm to identify women 
with a history of GDM searched all laboratory results as well as the problem list. Women 
aged 12–55 years who had either failed a 100-gm oral glucose tolerance test by Carpenter-
Coustan criteria or had GDM in the problem list were identified as probable GDM cases. To 
exclude women who had already been screened, the algorithm then excluded women who 
had a 75-gm oral glucose tolerance test within the past year. Of note, at this point in time 
both Brigham and Women’s Hospital and Massachusetts General Hospital use the two-step 
screening method for GDM and therefore patients receiving prenatal care within either 
system would not have undergone a 75-gm OGTT during pregnancy. The algorithm 
excluded women less than 3 months postpartum, by searching for a weight documented 
within the obstetric record within the past 3 months. Finally, it excluded women with a 
coded diagnosis of diabetes in the problem list. Reminders were generated within the system 
and logged electronically, but were not visible to providers outside of the participating sites.
Baseline patient characteristics including age, self-reported race and insurance status were 
collected from the electronic health record. Body mass index (BMI) was calculated from the 
last documented height and weight prior to the index visit at which intervention status was 
assigned. Provider characteristics including age and gender were collected from 
administrative databases. We used laboratory databases to identify the date, time and result 
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of the first testing performed. We defined our primary outcome of diabetes screening as 
performance of a hemoglobin A1C, 2-hour 75 gm oral glucose tolerance test, or fasting 
glucose during the study period.
We compared patient and provider characteristics at enrolled sites using t-tests for 
continuous covariates and chi squares for categorical covariates. We compared unadjusted 
rates of screening in interventions versus controls using a chi square. We used a mixed 
effects model (PROC GENMOD in the SAS statistical package) to account for clustering of 
patients within clinical sites. The model was then adjusted for patient age, race, BMI and 
insurance status, provider age and sex and whether GDM was included as a coded problem 
in the electronic problem list. We performed sensitivity analyses to estimate the impact of 
the reminder within a group of women without demographic risk factors for diabetes by 
comparing screening rates in the population restricted to normal weight women, and also in 
women who did not have GDM in the electronic problem list.
We estimated that a sample size of 1000 participants would be needed to give us 80% power 
to detect a 15% absolute difference in screening rates between the control and intervention 
arms when adjusting for an intracluster correlation coefficient of 0.05 and a mean cluster 
size of 50 patients.(14) Based on our actual mean cluster size of 33 patients, a sample size of 
850 participants gave us greater than 80% power to detect a 15% absolute difference in 
screening rates between the control and intervention arms.
Results
There were 6439 women with a history of GDM identified during the study period, of whom 
847 visited an eligible primary care provider at a participating clinic. Of those patients, 376 
(44.4%) were first seen at a control site and 471 (55.6%) were first seen at an intervention 
site. Patients were a mean of 41.0 ± 7.3 years old, and 47% were Caucasian. Women seen at 
intervention sites were less likely to have private insurance (65% vs. 72%, p=0.03) and more 
likely to have GDM as a coded problem within the LMR problem list than women at control 
sites (86% vs. 75%, p<0.0001) but were otherwise similar to women at the control sites. 
Providers at intervention sites were younger (mean age 42.9 ± 10.6 years versus 46.6 ± 11.7 
years, p<0.0001) than providers at control sites (Table 1).
A mean of 2.0 ± 1.6 reminders were generated per patient; this did not differ between 
intervention sites, where reminders were visible, and control sites, where the reminders were 
not visible to providers. During the study period, 265 (56%) of eligible patients at 
intervention sites were screened compared to 206 (55%) of eligible patients at control sites 
(p=0.67). The majority of women who were screened had a hemoglobin A1C performed 
(N=242 of 265 (91%) screened in the intervention group vs. 194 of 206 (94.1%) screened in 
the control group, table 2). There was no significant difference in the number of cases of 
diabetes identified in patients at intervention sites (N=22/471, 4.7%) compared with those at 
control sites (N=15/376, 4%) (p=0.74). There was no significant difference in the proportion 
of women screened on the same day as the first visit during the study period (22% of 
intervention subjects vs. 21% of control subjects, p=0.52). Among the patients at an 
Zera et al. Page 4













intervention site, the coded response “Done” or “Done Elsewhere” was selected infrequently 
(N=48, 10.2%).
Adjustment for cluster effects, patient and provider characteristics did not change the effect 
estimate of the reminder. The electronic reminder was not associated with diabetes screening 
(adjusted OR 1.04, 95% CI 0.79, 1.38). In the final adjusted model, only patient-level 
predictors were significantly associated with screening. For each unit increase in BMI, there 
was a 4% increased odds of screening, while non-white race was associated with a 2-fold 
increased odds of screening (table 3).
Among the 321 women with a normal BMI, 82 (45%) of intervention subjects were screened 
compared to 58 (41%) of control subjects (p=0.49). Among the 164 women without a 
history of GDM documented in the electronic problem list, 51% of the control subjects were 
screened compared with 60% of the intervention subjects (p=0.24).
Discussion
In our study, 55% of women with prior GDM were screened for diabetes. An electronic 
health record reminder had no effect on the rate of diabetes screening. Patient race and BMI 
were significant predictors of screening.
This study has several strengths. We were able to include a diverse cohort of women with 
prior GDM as well as a broad representation of medical practices. Unlike previous 
postpartum screening studies, our study evaluated screening after the postpartum period in a 
primary care setting.
Our results must be interpreted in the context of the limitations of our study design. The 
algorithm to identify at-risk women included a search for GDM in the problem list, thus a 
system-wide change to allow GDM to remain an active problem after delivery was 
implemented prior to the study start date. It is therefore possible that allowing providers to 
see GDM in the problem list was in and of itself an intervention in both arms of the study. In 
a secondary analysis including only women without GDM in the problem list we found no 
significant difference in the proportion screened, however by restricting the population we 
were underpowered for small differences in screening rates. Another potential explanation 
for our findings is that the reminder was passive and designed to have a low impact on 
provider workflow, and therefore may have been overlooked. We were unable to assess how 
many providers noticed the reminder but did not acknowledge with a coded response, and as 
many sites used paper lab orders at the time of the study, we were unable to assess the 
number of women for whom screening was ordered but not done. While we attempted to 
limit the intervention to primary care providers, it is also possible that patients were seen for 
problem visits rather than preventive care visits and therefore that screening was deferred.
Our intervention was directed only at providers, and patient-level factors were significantly 
associated with screening. Fewer women in the intervention arm were privately insured, a 
patient-level predictor associated with screening in other studies. It is possible that this 
baseline difference biased our findings toward a null result, even though we did not see any 
association with insurance status and screening in our adjusted model. Patient race and BMI 
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were associated with screening, suggesting that providers screened women they were able to 
easily identify as at risk. Although HbA1C is less sensitive than an OGTT for diabetes 
screening, it was the test performed for nearly all women who were screened, highlighting 
the difficulty of obtaining fasting tests that require subsequent visits.
Our screening rates were similar to those reported within the first year postpartum. (7) 
Retrospective studies of quality improvement initiatives to increase postpartum diabetes 
screening in women with prior GDM that included both provider and patient-level 
interventions suggested that provider reminders may be effective (10, 15). Clark reported a 
successful pilot randomized trial of patient and provider reminders to improve postpartum 
screening, however screening rates were lower in clinical practice (28%) than in the trial 
(60%).(16) Our study extends the existing literature to include a randomized trial in a 
primary care setting beyond the postpartum period
Electronic health records represent a promising technology for quality improvement and are 
widely used. However our study shows that a passive reminder is not sufficient to change 
performance. We hypothesize that a multi-pronged approach, including actionable reminders 
that facilitate care plans as well as patient-facing technology to engage women in their own 
care, is needed to improve diabetes screening for women with a history of GDM.
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Study flow. *Mean cluster size (n=29); range (n=3–91). †Mean cluster size (n=36); range 
(n=10–94).
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Table 1
Patient and Provider Characteristics among Enrolled Clinics
Control Intervention p
N (%) 376 (42.3) 471 (57.7)
Patient characteristics
Age, mean ± SD 41.1 ± 7.3 40.9 ± 7.3 NS1
Race, N (%) NS
Caucasian 186 (49.5) 215 (45.7)
Black/African American 52 (13.8) 66 (14.0)
Hispanic 76 (20.2) 127 (27.0)
Asian 52 (13.8) 50 (10.6)
Other or unknown 10 (2.7) 13 (2.7)
Privately insured, N (%) 272 (72.3) 307 (65.2) 0.03
BMI in kg/m2, mean ± SD 30.0 ± 6.9 29.3 ± 6.9 NS
GDM in EMR problem list, N (%) 280 (74.5) 403 (85.6) <0.001
Provider characteristics
Age in years, mean ± SD 46.6 ± 11.7 42.9 ± 10.6 <0.001
Male, N (%) 103 (27.4) 106 (22.8) NS
1
NS: non-significant (p>0.05)
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Table 2
Diabetes Screening in Participating Clinics
Control Intervention P
N 376 471
Number of reminders generated, mean ± SD 2.1 ± 1.6 2.0 ± 1.5 NS2
Screened, N (%) 206 (54.0) 265 (56.3) NS
Hemoglobin A1C 194 (94.2) 242 (91.1) NS
OGTT 14 (3.7) 14 (2.8) NS
Fasting glucose 22 (5.9) 27 (5.7) NS
Coded response "Done" 1 (0.3) 48 (10.2) <0.001
Screened same day, N (%) 77 (20.5) 105 (22.3) NS
Diabetes, N (%) 15 (4.0) 22 (4.7) NS
2
NS: non-significant (p>0.05)
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Table 3
Multivariate Model: Odds of Diabetes Screening
Model 13 Model 24
Predictor Odds Ratio 95% CI
Adjusted
Odds Ratio 95% CI
Reminder 1.06 0.79–1.43 1.04 0.79–1.38
Age, per year 1.02 0.997–1.04
BMI, per kg/m2 1.045 1.01–1.08
Non-white race 2.14 1.57–2.92
Private Insurance 1.28 0.87–1.87
Provider age, per year 1.01 0.99–1.03
Male provider 1.01 0.68–1.49
GDM in problem list 1.02 0.72–1.44
3
Adjusted for cluster effect
4
Adjusted for cluster effect, age, BMI, race, private insurance, provider age and sex, and presence of GDM in the problem list.
5
Significant associations bolded for emphasis
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